An observational study in Alpha-1 Antitrypsin Deficiency, sponsored by University of Florida. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-11-24.
Sponsored by University of Florida · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States — 17 open to participants now, 22 under way, 5 of them phase 3. alpha 1-Antitrypsin Deficiency · United States.
Among the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, this one has the largest planned enrollment of the 26 observational ones that give a count, is one of 2 that started in 2001, is one of 26 observational ones, reaches primary completion later than 20 of the 20 other live ones, and was the 15th registered.
142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.
Browse alpha 1-Antitrypsin Deficiency studies →17 of the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States are open now. Recruiting first, the newest first:
Grifols Therapeutics LLC · Sites in United States, Denmark, Germany and 6 more countries
Ages 18–80
Tessera Therapeutics, Inc. · Sites in United States, Australia, Netherlands and 2 more countries
Ages 18–70
University of Alabama at Birmingham · Sites in United States
Ages 19+
Columbia University · Sites in United States
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 28 · Phase 3 11 · Phase 4 4
First in 1995; this study’s year is marked. 2 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50,000 is above the median of 160 across 46 observational studies indexed under alpha 1-Antitrypsin Deficiency.
Median enrollment 30 across the 55 interventional studies, 190 across the 26 observational. Of the 57 that completed or were terminated, 29 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 81 have an industry lead sponsor. The 10 most frequent:
University of Florida is the lead sponsor of 1,290 studies on the registry; 202 are open to participants now.
Of its 181 completed or terminated interventional studies of FDA-regulated products, 143 (79%) have results posted.
University of Florida has 6 studies filed under alpha 1-Antitrypsin Deficiency — fewer than ten, so there is no comparison to draw.
3 of the studies in alpha 1-Antitrypsin Deficiency with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT05297812Columbia UniversityAlpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease | 2027-01 |
| NCT07135427University of Alabama at BirminghamGenetic Variation in IgG in Alpha 1 Antitrypsin Deficiency | 2027-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Alpha-1 Coded Testing (ACT) Study was established to study genetic testing and outcomes of individuals at risk for alpha-1 antitrypsin deficiency.
Genetic testing for alpha-1 antitrypsin deficiency is sometimes delayed despite established testing indications. All genetic tests have risks and possible benefits. The ACT study evaluates the population demographics, reasons for testing, and outcomes through a confidential testing program. Co-morbidities of alpha-1 antitrypsin deficiency other than lung and liver disease are being investigated. Concerns about genetic confidentiality are lessened in this study by a coded testing procedure that returns results through the mail to study participants.
Individuals choosing to test at home for alpha-1 antitrypsin deficiency.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Home fingerstick testing for alpha-1 antitrypsin genotype
Structured questionnaire responses on the risks and benefits of testing.
Rotating questionnaires assess the clinical course and co-morbidities associated with different genotypes of alpha-1 antitrypsin deficiency.
Time frame: Before and after alpha-1 antitrypsin testing
Plan to share: No
Started Jan 2001 (actual). Primary completion is estimated for Jan 2050, 588 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
alpha 1-Antitrypsin Deficiency →